Patents
US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026
8 patents granted to the 3 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to DiaMedica Therapeutics Inc.’s names, not what it holds today.
Patents granted
8
8 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 1 in 2024 and none in 2023
Applications published
25
3 of them in 2025
Names they are printed under
3
a former name, its own name
By yearGrantedApplications published
'05'07'09'10'11'12'13'14'15'16'17'21'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name3 counted
DiaMedica Inc. a former name
CA, as the owner printed on each patent
14 publishedDiaMedica Inc. a former name
named as the applicant on its applications, in CA
9 publishedDiaMedica Therapeutics, Inc. its own name
named as the applicant on its applications, in US
2 published
Newest grantseach row opens the USPTO’s own copy
| Granted | Patent | Title | Field | Owner as printed |
|---|
| Jun 17, 2025 | 12,329,805 | Dosage forms of tissue kallikrein 1 | Pharmaceuticals | DiaMedica Inc. |
| Jan 2, 2024 | 11,857,608 | Dosage forms of tissue kallikrein 1 | Pharmaceuticals | DiaMedica Inc. |
| Dec 12, 2017 | 9,839,678 | Human tissue kallikrein 1 glycosylation isoforms | Pharmaceuticals | DiaMedica Inc. |
| Apr 11, 2017 | 9,616,015 | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods | Pharmaceuticals | DiaMedica Inc. |
| Jun 14, 2016 | 9,364,521 | Human tissue kallikrein 1 glycosylation isoforms | Pharmaceuticals | DiaMedica Inc. |
| Mar 18, 2014 | 8,673,964 | Use of drug combinations for treating insulin resistance | Pharmaceuticals | DiaMedica Inc. |
| Aug 6, 2013 | 8,501,695 | Tissue kallikrein for the treatment of diseases associated with amyloid protein | Pharmaceuticals | DiaMedica Inc. |
| Nov 24, 2009 | 7,622,447 | Use of glutathione synthesis stimulating compounds in reducing insulin resistance | Pharmaceuticals | DiaMedica Inc. |
Newest applications publishedan application is a clue, never a plan
| Published | Application | Title | Field | Owner as printed |
|---|
| Nov 6, 2025 | 2025/0339500 | DOSAGE FORMS OF TISSUE KALLIKREIN 1 | Pharmaceuticals | DiaMedica Inc. |
| Oct 16, 2025 | 2025/0319167 | INTRAVENOUS COMPOSITIONS OF TISSUE KALLIKREIN-1 AND RELATED METHODS | Pharmaceuticals | DiaMedica Therapeutics, Inc. |
| Jul 31, 2025 | 2025/0242001 | TISSUE KALLIKREIN-1 FOR TREATING PREGNANCY DISORDERS | Pharmaceuticals | DiaMedica Therapeutics, Inc. |
| Jul 18, 2024 | 2024/0238389 | DOSAGE FORMS OF TISSUE KALLIKREIN 1 | Pharmaceuticals | DiaMedica Inc. · patent 12,329,805 granted from it |
| Dec 28, 2023 | 2023/0414727 | TISSUE KALLIKREIN-1 FOR TREATING CHRONIC KIDNEY DISEASE | Biotechnology | DiaMedica Inc. |
| May 13, 2021 | 2021/0138045 | DOSAGE FORMS OF TISSUE KALLIKREIN 1 | Pharmaceuticals | DiaMedica Inc. · patent 11,857,608 granted from it |
| Nov 30, 2017 | 2017/0340559 | FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS | Pharmaceuticals | DiaMedica Inc. |
| May 4, 2017 | 2017/0119862 | HUMAN TISSUE KALLIKREIN 1 GLYCOSYLATION ISOFORMS | Pharmaceuticals | DiaMedica Inc. · patent 9,839,678 granted from it |
| Jan 7, 2016 | 2016/0000704 | FORMULATIONS OF HUMAN TISSUE KALLIKREIN-1 FOR PARENTERAL DELIVERY AND RELATED METHODS | Pharmaceuticals | DiaMedica Inc. · patent 9,616,015 granted from it |
| Jul 16, 2015 | 2015/0196624 | HUMAN TISSUE KALLIKREIN 1 GLYCOSYLATION ISOFORMS | Pharmaceuticals | DiaMedica Inc. · patent 9,364,521 granted from it |
What it applied for, 2024 to 2025: Pharmaceuticals 4.
A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.